연구용
제품 번호S1082
| 세포주 | 분석 유형 | 농도 | 배양 시간 | 제형 | 활성 설명 | PMID |
|---|---|---|---|---|---|---|
| IGROV-1 | Growth Inhibition Assay | IC50=0.07248 μM | SANGER | |||
| HCE-T | Growth Inhibition Assay | IC50=1.32247 μM | SANGER | |||
| D-542MG | Growth Inhibition Assay | IC50=1.86737 μM | SANGER | |||
| 23132-87 | Growth Inhibition Assay | IC50=4.40147 μM | SANGER | |||
| HDLM-2 | Growth Inhibition Assay | IC50=8.04766 μM | SANGER | |||
| ACN | Growth Inhibition Assay | IC50=8.50109 μM | SANGER | |||
| HuO-3N1 | Growth Inhibition Assay | IC50=9.60108 μM | SANGER | |||
| BHT-101 | Growth Inhibition Assay | IC50=11.38 μM | SANGER | |||
| KYSE-150 | Growth Inhibition Assay | IC50=11.5841 μM | SANGER | |||
| MC-IXC | Growth Inhibition Assay | IC50=12.2292 μM | SANGER | |||
| D-423MG | Growth Inhibition Assay | IC50=12.7657 μM | SANGER | |||
| NY | Growth Inhibition Assay | IC50=14.8903 μM | SANGER | |||
| HOS | Growth Inhibition Assay | IC50=15.6719 μM | SANGER | |||
| NB7 | Growth Inhibition Assay | IC50=15.891 μM | SANGER | |||
| DMS-273 | Growth Inhibition Assay | IC50=16.6713 μM | SANGER | |||
| MDA-MB-361 | Growth Inhibition Assay | IC50=17.2711 μM | SANGER | |||
| DU-145 | Growth Inhibition Assay | IC50=18.32 μM | SANGER | |||
| NCI-H82 | Growth Inhibition Assay | IC50=19.8386 μM | SANGER | |||
| NCI-SNU-1 | Growth Inhibition Assay | IC50=20.0196 μM | SANGER | |||
| GCT | Growth Inhibition Assay | IC50=20.8824 μM | SANGER | |||
| C2BBe1 | Growth Inhibition Assay | IC50=21.1058 μM | SANGER | |||
| LB2241-RCC | Growth Inhibition Assay | IC50=21.8441 μM | SANGER | |||
| COLO-829 | Growth Inhibition Assay | IC50=22.1871 μM | SANGER | |||
| EW-11 | Growth Inhibition Assay | IC50=22.8022 μM | SANGER | |||
| NCI-H526 | Growth Inhibition Assay | IC50=23.4717 μM | SANGER | |||
| SF295 | Growth Inhibition Assay | IC50=24.0252 μM | SANGER | |||
| D-566MG | Growth Inhibition Assay | IC50=25.2943 μM | SANGER | |||
| 8505C | Growth Inhibition Assay | IC50=25.6331 μM | SANGER | |||
| HT-29 | Growth Inhibition Assay | IC50=26.0431 μM | SANGER | |||
| NBsusSR | Growth Inhibition Assay | IC50=26.8006 μM | SANGER | |||
| BV-173 | Growth Inhibition Assay | IC50=28.3182 μM | SANGER | |||
| CTB-1 | Growth Inhibition Assay | IC50=30.1031 μM | SANGER | |||
| JAR | Growth Inhibition Assay | IC50=32.5371 μM | SANGER | |||
| CAMA-1 | Growth Inhibition Assay | IC50=33.4615 μM | SANGER | |||
| CAL-51 | Growth Inhibition Assay | IC50=34.7176 μM | SANGER | |||
| A172 | Growth Inhibition Assay | IC50=37.4921 μM | SANGER | |||
| QIMR-WIL | Growth Inhibition Assay | IC50=38.0708 μM | SANGER | |||
| AsPC-1 | Growth Inhibition Assay | IC50=38.4651 μM | SANGER | |||
| MKN7 | Growth Inhibition Assay | IC50=39.0079 μM | SANGER | |||
| ONS-76 | Growth Inhibition Assay | IC50=43.3057 μM | SANGER | |||
| RS4-11 | Growth Inhibition Assay | IC50=44.0752 μM | SANGER | |||
| NOS-1 | Growth Inhibition Assay | IC50=44.6031 μM | SANGER | |||
| A101D | Growth Inhibition Assay | IC50=44.8023 μM | SANGER | |||
| HCC1806 | Growth Inhibition Assay | IC50=46.1148 μM | SANGER | |||
| CAL-27 | Growth Inhibition Assay | IC50=47.7246 μM | SANGER | |||
| BT-549 | Growth Inhibition Assay | IC50=48.5315 μM | SANGER | |||
| LCLC-97TM1 | Growth Inhibition Assay | IC50=49.2413 μM | SANGER | |||
| A4-Fuk | Growth Inhibition Assay | IC50=49.849 μM | SANGER | |||
| OVCAR-4 | Growth Inhibition Assay | IC50=50.0601 μM | SANGER | |||
| HD-MY-Z | Growth Inhibition Assay | IC50=50.7764 μM | SANGER | |||
| NCI-H292 | Growth Inhibition Assay | IC50=50.8758 μM | SANGER | |||
| Sk-ChA-1 | Growth Inhibition Assay | 0.25–50 μM | 72 h | IC50=74.54±2.58μM | 25742482 | |
| Mz-ChA-1 | Growth Inhibition Assay | 0.25–50 μM | 72 h | IC50=54.97±3.45μM | 25742482 | |
| Smo-WT | Growth Inhibition Assay | IC50 of 14 nM | 24291104 | |||
| Smo-D473H | Growth Inhibition Assay | IC50 of 7.1 μM | 24291104 | |||
| K562 | Function Assay | 10 μM | 72 h | reduces the expression of Gli1 | 23319824 | |
| T315I BCR-ABL BaF3 | Function Assay | 10 μM | 72 h | reduces the expression of Gli1 | 23319824 | |
| TF-1 BCR-ABL | Function Assay | 10 μM | 72 h | reduces the expression of Gli1 | 23319824 | |
| Shh-Light 2 | Function assay | 2 days | Antagonist activity at Smo in mouse Shh-Light 2 cells assessed as inhibition of Shh-induced Gli1-reporter activity after 2 days by dual-luciferase reporter gene method, IC50 = 0.0015 μM. | 23063522 | ||
| NIH/3T3 | Function assay | Inhibition of hedgehog signaling (unknown origin) expressed in mouse NIH/3T3 cells by Gli-dual-luciferase reporter assay, IC50 = 0.0023 μM. | 27180012 | |||
| NIH/3T3 Light2 | Function assay | Inhibition of hedgehog signaling pathway in mouse NIH/3T3 Light2 cells by Gli-luciferase reporter gene assay, IC50 = 0.0023 μM. | 28688278 | |||
| Light2 | Function assay | 48 hrs | Inhibition of hedgehog signaling pathway in mouse Light2 cells after 48 hrs by Gli-luciferase reporter gene assay, IC50 = 0.00246 μM. | 29739714 | ||
| HEPM | Function assay | Inhibition of SHH in human HEPM cells by Gli-luciferase reporter gene assay, INH = 0.0028 μM. | 19716296 | |||
| Shh Light2 | Function assay | Inhibition of SHH in mouse Shh Light2 cells by GLI-responsive firefly luciferase reporter gene assay, IC50 = 0.003 μM. | 19309080 | |||
| HEPM | Function assay | Inhibition of Hedgehog signaling in human HEPM cells assessed as reduction in receptor-mediated Gli1 mRNA expression by reporter gene assay, INH = 0.003 μM. | 20875741 | |||
| C3H10T1/2 | Function assay | 20 hrs | Inhibition of Smo in mouse C3H10T1/2 cells using human recombinant SHH assessed as effect on SMO/SHH transient transcriptional activation after 20 hrs by Gli-luciferase reporter assay, IC50 = 0.005 μM. | 24900436 | ||
| NIH/3T3 | Function assay | 24 hrs | Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells measured after 24 hrs by Gli-dual luciferase reporter gene assay, IC50 = 0.005 μM. | 27810591 | ||
| NIH3T3 | Function assay | 48 hrs | Inhibition of smo-mediated hedgehog signaling pathway in mouse NIH3T3 cells expressing GRE-Luc reporter gene assessed as inhibition of SAG-induced GRE-Luc reporter activity after 48 hrs by luminescence assay, IC50 = 0.006 μM. | 29499483 | ||
| Shh-light2 | Function assay | Inhibition of Smo-mediated Hh signaling in human Shh-light2 cells by luciferase reporter gene assay, IC50 = 0.007 μM. | 22268551 | |||
| HEK293 | Function assay | 2 hrs | Displacement of BODIPY-labelled cyclopamine from human Smo receptor expressed in HEK293 cells after 2 hrs by fluorescence microscopy, IC50 = 0.007 μM. | 22268551 | ||
| NIH3T3 | Function assay | Inhibition of hedgehog receptor signaling pathway in mouse NIH3T3 cells transfected with Gli-reporter gene by luciferase reporter gene assay, IC50 = 0.00717 μM. | 24923765 | |||
| NIH/3T3 | Function assay | 48 hrs | Inhibition of Hedgehog signaling pathway in mouse NIH/3T3 cells assessed as reduction in Sonic hedgehog-induced Gli luciferase activity after 48 hrs by Dual-luciferase reporter gene assay, IC50 = 0.00717 μM. | 30249494 | ||
| NIH3T3 | Function assay | 48 hrs | Inhibition of hedgehog signalling in mouse NIH3T3 cells stably transfected with Gli-luciferase construct incubated for 48 hrs by dual luciferase reporter gene assay, IC50 = 0.0072 μM. | 26827136 | ||
| NIH3T3 | Function assay | 48 hrs | Inhibition of Sonic-induced hedgehog signalling in mouse NIH3T3 cells after 48 hrs by Gli-luciferase reporter assay, IC50 = 0.0072 μM. | 26820554 | ||
| NIH3T3 | Function assay | 48 hrs | Inhibition of SHH signaling pathway in mouse NIH3T3 cells measured after 48 hrs by Gli-luciferase reporter assay, IC50 = 0.0072 μM. | 24176396 | ||
| NIH/3T3 | Function assay | 48 hrs | Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells after 48 hrs by Gli-luciferase reporter gene assay, IC50 = 0.0072 μM. | 24486203 | ||
| NIH/3T3 | Function assay | Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells by Gli1-luciferase reporter gene assay, IC50 = 0.0072 μM. | 24405704 | |||
| NIH/3T3 | Function assay | Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells carrying stably transfected Gli-reporter construct by luciferase reporter assay, IC50 = 0.0072 μM. | 28642101 | |||
| C3H10T1/2 | Function assay | 6 hrs | Inhibition of SAG-induced differentiation of mouse mesenchymal pluripotent C3H10T1/2 cells to alkaline phosphatase positive oeseoblasts after 6 hrs, IC50 = 0.011 μM. | 22268551 | ||
| HCC827 | Function assay | Displacement of [3H]-cyclopamine from SMO V404M mutant in gefitinib resistant human HCC827 cells by scintillation counting, Ki = 0.0122 μM. | 28787156 | |||
| C3H10T1/2 | Function assay | Inhibition of SHH in mouse C3H10T1/2 cells by Gli-luciferase reporter gene assay, IC50 = 0.013 μM. | 19716296 | |||
| S12 | Function assay | Inhibition of Hedgehog signaling in mouse S12 cells assessed as reduction in receptor-mediated Gli1 mRNA expression by reporter gene assay, INH = 0.013 μM. | 20875741 | |||
| TM3 | Function assay | 48 hrs | Inhibition of Hh signaling pathway in mouse TM3 cells assessed as downregulation of Gli1 gene expression after 48 hrs by luciferase reporter gene assay, EC50 = 0.013 μM. | 26976215 | ||
| NIH/3T3 | Function assay | Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells expressing wild type Smo assessed as reduction in Gli mRNA expression by RT-PCR method, IC50 = 0.0144 μM. | 27810591 | |||
| S12 | Function assay | 48 hrs | Inhibition of human SHH pathway in mouse S12 cells assessed as GLI-mediated transcriptional activity after 48 hrs by luciferase reporter gene assay, IC50 = 0.015 μM. | 21438527 | ||
| NIH/3T3 | Function assay | Inhibition of SMO in mouse NIH/3T3 cells assessed as inhibition of SAG-induced hedgehog-mediated luminescence signaling by GRE-luciferase reporter gene assay, IC50 = 0.016 μM. | 26119500 | |||
| U2OS | Function assay | 2 hrs | Displacement of [3H]cyclopamine from wild type Smo expressed in U2OS cells after 2 hrs by scintillation counting, Ki = 0.0162 μM. | 23063522 | ||
| NIH3T3 | Function assay | 30 hrs | Inhibition of Smo receptor (unknown origin) expressed in NIH3T3 cells assessed as inhibition of Smo agonist SAG-induced GRE activation after 30 hrs by luciferase reporter gene assay, IC50 = 0.023 μM. | 24726807 | ||
| medulloblastoma cell | Antiproliferative assay | 36 hrs | Antiproliferative activity against Ptch+/- and p53-/- mouse medulloblastoma cells after 36 hrs by Brdu incorporation assay, IC50 = 0.0304 μM. | 28688278 | ||
| Shh Light2 | Function assay | Antagonist activity at smoothened (unknown origin) expressed in mouse Shh Light2 cells co-expressing Gli-dependent reporter gene assessed as inhibition of Hh signaling by dual luciferase reporter gene assay, IC50 = 0.033 μM. | 24491459 | |||
| Light2 | Function assay | Inhibition of hedgehog signaling pathway in mouse Light2 cells in Shh conditioned medium by Gli-luciferase reporter gene assay, IC50 = 0.039 μM. | 28873303 | |||
| Shh Light2 | Function assay | Inhibition of Smo-mediated Hh signalling pathway in mouse Shh Light2 cells by Gli-luciferase reporter gene assay, IC50 = 0.0392 μM. | 27736063 | |||
| ASZ001 | Function assay | 48 hrs | Inhibition of Hedgehog signaling in mouse ASZ001 cells assessed as downregulation of Gli1 mRNA expression after 48 hrs by RT-PCR analysis, IC50 = 0.04 μM. | 24900716 | ||
| NIH/3T3 | Function assay | 48 hrs | Antagonist activity at Smo receptor in mouse NIH/3T3 cells harboring GRE-Luc assessed as inhibition of SAG-induced Hh signaling pathway preincubated with cells followed by SAG addition measured after 48 hrs by luciferase reporter gene assay, IC50 = 0.046 μM. | 29857275 | ||
| Light2 | Function assay | 30 hrs | Inhibition of hedgehog signaling pathway in mouse Light2 cells in Shh conditioned medium after 30 hrs by Gli-Renilla luciferase reporter gene assay, IC50 = 0.05 μM. | 30099257 | ||
| C3H10T1/2 | Function assay | 6 days | Inhibition of hedgehog signaling pathway-mediated differentiation of mouse C3H10T1/2 cells assessed as decrease in SAG-induced ALP activity after 6 days by chemiluminescence-based assay, IC50 = 0.05 μM. | 30099257 | ||
| DaOY | Function assay | 48 hrs | Inhibition of Hedgehog signaling in human DaOY cells assessed as downregulation of Gli1 mRNA expression after 48 hrs by RT-PCR analysis, IC50 = 0.086 μM. | 24900716 | ||
| C3H10T1/2 | Function assay | 1 hr | Inhibition of Hedgehog signaling pathway in mouse C3H10T1/2 cells assessed as reduction in purmorphamine-induced increase in alkaline phosphatase level using CDP-star as substrate pretreated for 1 hr followed by purmorphamine addition measured after 5 day, IC50 = 0.14 μM. | 28947939 | ||
| M210B4 | Function assay | 24 hrs | Inhibition of Hedgehog signaling in mouse M210B4 cells assessed as downregulation of Ptch mRNA expression after 24 hrs by RT-PCR analysis, IC50 = 0.14 μM. | 24900716 | ||
| M210B4 | Function assay | 24 hrs | Inhibition of Hedgehog signaling in mouse M210B4 cells assessed as downregulation of Gli1 mRNA expression after 24 hrs by RT-PCR analysis, IC50 = 0.2 μM. | 24900716 | ||
| Shh Light2 | Function assay | 1 hr | Inhibition of Hedgehog signaling in mouse Shh Light2 cells assessed as reduction in purmorphamine-induced Gli mediated transcriptional activity pretreated for 1 hr followed by purmorphamine addition measured after 48 hrs by luciferase reporter gene assay, IC50 = 0.98 μM. | 28947939 | ||
| NIH/3T3 | Function assay | Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells harboring Smo D477H mutant assessed as reduction in Gli mRNA expression by RT-PCR method, IC50 = 1.196 μM. | 27810591 | |||
| S12 | Function assay | 48 hrs | Inhibition of human SHH pathway in mouse S12 cells assessed as GLI-mediated transcriptional activity after 48 hrs by luciferase reporter gene assay in presence of 0.5 mg/mL human alpha-1-acid glycoprotein, IC50 = 1.75 μM. | 21438527 | ||
| Calu6 | Function assay | 4 hrs | Plasma concentration in human Calu6 cells xenografted in nude mouse at 75 mg/kg, po bid measured after 4 hrs post fifth dose, Cp = 23 μM. | 19716296 | ||
| Calu-6 | Function assay | Plasma concentration in Calu-6 cells xenografted nude mouse PK/PD model at 75 mg/kg, po bid for 5 days measured 4 hrs post last dose relative to untreated control, Cp = 23 μM. | 20875741 | |||
| T47D | Cytotoxicity assay | 72 hrs | Cytotoxicity against human T47D cells after 72 hrs by MTT assay, IC50 = 41.34 μM. | 29107429 | ||
| LS180 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human LS180 cells after 72 hrs by sulforhodamine-B assay, IC50 = 45 μM. | 30099257 | ||
| LS174T | Antiproliferative assay | 72 hrs | Antiproliferative activity against human LS174T cells after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 45.81 μM. | 26820554 | ||
| BxPC3 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human BxPC3 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 47.95 μM. | 26820554 | ||
| medulloblastoma cell | Antitumor assay | Antitumor activity against mouse medulloblastoma cells xenografted in Ptch +/- mouse assessed as decrease in tumor volume at 12.5 mg/kg, po bid. | 19716296 | |||
| S12 | Function assay | 48 hrs | Inhibition of human SHH pathway in mouse S12 cells assessed as GLI-mediated transcriptional activity after 48 hrs by luciferase reporter gene assay in presence of 1 mg/mL human alpha-1-acid glycoprotein. | 21438527 | ||
| Shh Light2 | Function assay | 0.1 uM | 36 hrs | Inhibition of Smo-mediated Hh signalling pathway in mouse Shh Light2 cells assessed as suppression of Gli1-mRNA expression at 0.1 uM measured after 36 hrs by RT-qPCR analysis. | 27736063 | |
| SW1353 | Antiproliferative assay | 10 uM | 48 hrs | Antiproliferative activity against human SW1353 cells assessed as growth inhibition at 10 uM after 48 hrs by MTT assay. | 24491459 | |
| DaOY | Antiproliferative assay | 10 uM | 48 hrs | Antiproliferative activity against human DaOY cells assessed as growth inhibition at 10 uM after 48 hrs by MTT assay. | 24491459 | |
| A549 | Antiproliferative assay | 10 uM | 48 hrs | Antiproliferative activity against human A549 cells assessed as growth inhibition at 10 uM after 48 hrs by MTT assay. | 24491459 | |
| HCT116 | Antiproliferative assay | 10 uM | 48 hrs | Antiproliferative activity against human HCT116 cells assessed as growth inhibition at 10 uM after 48 hrs by MTT assay. | 24491459 | |
| NIH/3T3 | Function assay | 10 uM | Inhibition of Hedgehog signaling in mouse NIH/3T3 cells assessed as down regulation of mPTCH1 mRNA expression at 10 uM. | 24491459 | ||
| MSC | Function assay | 20 to 80 uM | Inhibition of hedgehog signaling in mouse MSC cells assessed as down regulation of alkaline phosphatase at 20 to 80 uM. | 24491459 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells. | 29435139 | |||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells. | 29435139 | |||
| NIH3T3-Luc | Function assay | 1 uM | 48 hrs | Inhibition of smo-mediated hedgehog signaling pathway in mouse NIH3T3-Luc cells assessed as downregulation of Gli mRNA expression at 1 uM after 48 hrs by real-time PCR analysis. | 29499483 | |
| C3H10T1/2 | Function assay | 24 hrs | Inhibition of hedgehog signaling pathway-mediated GLI1 mRNA expression in mouse C3H10T1/2 cells after 24 hrs by RT-PCR analysis in presence of (1R,3aR,4S,7aR)-7a-methyl-1-((R)-6-methylheptan-2-yl)octahydro-1H-inden-4-yl 3-hydroxybenzoate. | 24730984 | ||
| C3H10T1/2 | Function assay | 24 hrs | Inhibition of hedgehog signaling pathway-mediated GLI1 mRNA expression in mouse C3H10T1/2 cells after 24 hrs by RT-PCR analysis in presence of VD3. | 24730984 | ||
| NIH/3T3 | Function assay | 100 nM | 36 hrs | Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells assessed as downregulation of Shh-induced Gli1 mRNA expression levels at 100 nM after 36 hrs by RT-qPCR analysis. | 28873303 | |
| C3H10T1/2 | Function assay | 100 nM | 36 hrs | Inhibition of hedgehog signaling pathway in mouse C3H10T1/2 cells assessed as downregulation of Shh-induced Gli1 mRNA expression levels at 100 nM after 36 hrs by RT-qPCR analysis. | 28873303 | |
| NIH/3T3 | Function assay | 100 nM | 36 hrs | Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells assessed as downregulation of Shh-induced ptch1 mRNA expression levels at 100 nM after 36 hrs by RT-qPCR analysis. | 28873303 | |
| C3H10T1/2 | Function assay | 100 nM | 36 hrs | Inhibition of hedgehog signaling pathway in mouse C3H10T1/2 cells assessed as downregulation of Shh-induced ptch1 mRNA expression levels at 100 nM after 36 hrs by RT-qPCR analysis. | 28873303 | |
| medulloblastoma cell | Antiproliferative assay | up to 30 uM | 72 hrs | Antiproliferative activity against mouse Ptch+/- p53-/- medulloblastoma cells assessed as reduction in cell proliferation up to 30 uM after 72 hrs by MTS assay. | 28873303 | |
| medulloblastoma cell | Apoptosis assay | Induction of apoptosis in mouse Ptch+/- p53-/- medulloblastoma cells implanted in athymic nude mouse at 12.5 mg/kg, ip bid for 15 consecutive days by TUNEL assay. | 28873303 | |||
| NIH/3T3 | Function assay | Inhibition of hedgehog signaling pathway expressed in mouse NIH/3T3 cells assessed as inhibition of hedgehog-induced Gli-2 accumulation at tip of primary cilia by DAPI staining based confocal microscopic analysis. | 27810591 | |||
| NIH/3T3 | Function assay | Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells assessed as inhibition of hedgehog-induced Smo-EGFP ciliary translocation by DAPI staining based confocal microscopic analysis. | 27810591 | |||
| medulloblastoma cell | Anti-tumor assay | Anti-tumor activity against mouse Ptch+/- p53-/- medulloblastoma cells implanted in athymic nude mouse assessed as tumor growth inhibition at 20 mg/kg, po administered twice daily via gavage measured every other day during compound dosing. | 29739714 | |||
| C3H10T1/2 | Function assay | 4.1 to 1000 nM | Allosteric inhibition of Smo in mouse C3H10T1/2 cells assessed as inhibition of purmorphamine-induced Gli1 transcriptional activity at 4.1 to 1000 nM by qPCr analysis. | 23074541 | ||
| C3H10T1/2 | Function assay | 4.1 to 1000 nM | Competitive inhibition of Smo in mouse C3H10T1/2 cells assessed as inhibition of SAG-induced Gli1 transcriptional activity at 4.1 to 1000 nM by qPCR analysis. | 23074541 | ||
| 클릭하여 더 많은 세포주 실험 데이터 보기 | ||||||
| 분자량 | 421.3 | 화학식 | C19H14Cl2N2O3S |
보관 (수령일로부터) | |
|---|---|---|---|---|---|
| CAS 번호 | 879085-55-9 | SDF 다운로드 | 원액 보관 |
|
|
| 동의어 | GDC-0449 | Smiles | CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl | ||
|
In vitro |
DMSO
: 84 mg/mL
(199.38 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)
2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)
계산 결과:
작업 농도: mg/ml;
DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.
참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.
| Targets/IC50/Ki |
Hedgehog
(Cell-free assay) 3 nM
|
|---|---|
| 시험관 내(In vitro) |
Vismodegib (GDC-0449)는 Hedgehog 신호 경로를 표적으로 하여 Hedgehog-리간드 세포 표면 수용체 PTCH 및/또는 SMO의 활동을 차단하고 Hedgehog 신호를 억제합니다. 이 화합물은 여러 ATP 결합 카세트(ABC) 수송체를 방지하고 MDR과 관련된 중요한 ABC 수송체인 ABCG2, Pgp 및 MRP1도 차단합니다. 이는 ABC 수송체, ABCG2/BCRP 및 ABCB1/Pgp의 강력한 억제제이며 ABCC1/MRP1의 약한 억제제입니다. ABCG2를 과발현하는 HEK293 세포에서 형광 ABCG2 기질 BODIPY의 보유를 증가시키고 이들 세포를 재감작시킵니다. Pgp 또는 MRP1을 과발현하도록 조작된 Madin-Darby canine kidney II 세포에서 칼세인-AM의 보유를 증가시키고 이들을 재감작시킵니다. 또한 SN-38에 반응하여 ABCG2를 과발현하는 인간 비소세포 폐암 세포 NCI-H460/par 및 NCI-H460/MX20을 재감작시킵니다. ABCG2 및 Pgp 예방을 위한 IC50 값은 각각 약 1.4 μM 및 3.0 μM입니다. 또한, 세포 내 Ca2+ 항상성을 변경하고 저항성 폐암 세포에서 세포 성장을 억제합니다. |
| 생체 내(In vivo) |
Vismodegib (GDC-0449)는 동물 모델에서 수아세포종 치료에 사용되었습니다. 이는 췌장 세포 증식을 비특이적으로 억제하지 않고 원발성 췌장 이종이식의 성장을 방지합니다. 이 화합물의 경구 투여는 Ptch(+/-) 수아세포종 동종이식 모델에서 ≥25 mg/kg 용량에서 종양 퇴행을 유발하고, 두 가지 리간드 의존성 대장암 모델인 D5123 및 1040830에서 1일 2회 투여 시 최대 92 mg/kg 용량에서 종양 성장 억제를 유발합니다. Hh 경로 활성 및 PK/PD 모델링 분석은 수아세포종 및 D5123 모델 모두에서 유사한 IC50으로 Gli1을 억제함을 보여줍니다(각각 0.165 μM 및 0.267 μM). 경로 조절은 통합 PK/PD 모델을 사용하여 효능과 연결되며, GDC-0449 활동의 > 50%가 Hh 경로의 > 80% 억제와 관련이 있는 가파른 관계를 나타냅니다. |
참조 |
|
| 방법 | 바이오마커 | 이미지 | PMID |
|---|---|---|---|
| Western blot | Fas / DR4 / DR5 / Cleaved PARP / Bcl-2 / Cleaved caspase-3 / PDGFRα p-GSK3β / GSK3β / p-Akt / Akt / Gli1 Gli1 / SOX2 / OCT4 p53 / Cyclin D1 / p21 Bcl-2 / Bax |
|
22087285 |
| Immunofluorescence | Gli1 / Gli2 |
|
22087285 |
| Growth inhibition assay | Cell viability |
|
29042665 |
(데이터 출처 https://clinicaltrials.gov, 업데이트 날짜 2024-05-22)
| NCT 번호 | 모집 | 조건 | 스폰서/협력자 | 시작일 | 단계 |
|---|---|---|---|---|---|
| NCT06344052 | Recruiting | Basal Cell Carcinoma |
Stamford Pharmaceuticals Inc. |
April 9 2024 | Phase 2 |
| NCT03610022 | Completed | Metastatic Basal Cell Carcinoma|Locally Advanced Basal Cell Carcinoma |
University Hospital Bordeaux |
September 3 2018 | Phase 4 |
| NCT03035188 | Completed | Basal Cell Carcinoma |
SRH Wald-Klinikum Gera GmbH |
January 2017 | Phase 2 |
| NCT02781389 | Completed | Basal Cell Carcinoma |
University Hospital Essen|OnkoDataMed GmbH |
April 29 2016 | -- |
| NCT02593760 | Completed | Myelofibrosis |
Hoffmann-La Roche |
January 25 2016 | Phase 1 |
| NCT02648048 | Completed | Idiopathic Pulmonary Fibrosis |
Hoffmann-La Roche |
January 15 2016 | Phase 1 |